Efficacy, safety and treatment satisfaction of transition to a regimen of insulin degludec/aspart: A pilot study

Table 1 Baseline characteristics of the participants, n (%)/mean ± SD

Characteristic	Patients (n = 21)
Age (year)	59.1 ± 12.6
Male, No. patients	8 (38.1)
BMI (kg/m2)	24.5 ± 3.5
WC (cm)	90.9 ± 9.6
WHR	0.9 ± 0.1
SBP (mmHg)	126.1 ± 18.7
DBP (mmHg)	74.8 ± 8.0
HR (bpm)	79.9 ± 11.8
Smoking, No. patients	5 (23.8)
Alcohol drinking, No. patients	4 (19.0)
Duration of diabetes (year)
< 10	3 (14.3)
10-20	10 (47.6)
> 20	8 (38.1)
Baseline insulin regimen, No. patients
Three times-daily premixed insulin	1 (4.8)
Basal–bolus insulin	20 (95.2)
Duration of insulin therapy (year)
< 5	9 (42.9)
5-10	6 (28.6)
> 10	6 (28.6)
Oral antidiabetic medicine, No. patients
Metformin	8 (38.1)
α-Glucosidase inhibitor	8 (38.1)
DPP-4 inhibitor	4 (19.0)
SGLT2 inhibitor	5 (23.8)
Complications, No. patients
Retinopathy	8 (38.1)
Nephropathy	11 (52.4)
Comorbidity, No. patients
CVD	4 (19.0)
Stroke	2 (9.5)

WHR: Waist-to-hip ratio; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; HR: Heart rate; CVD: Cardiovascular disease.